Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence.
Journal
NeoReviews
ISSN: 1526-9906
Titre abrégé: Neoreviews
Pays: United States
ID NLM: 101085360
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
entrez:
3
8
2021
pubmed:
4
8
2021
medline:
3
11
2021
Statut:
ppublish
Résumé
Children with sickle cell disease (SCD) are at risk for neurologic and cognitive complications beginning in early childhood. Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes. In this article, the prevalence, pathophysiology, and available interventions to prevent and treat neurologic and cognitive complications of SCD will be reviewed.
Identifiants
pubmed: 34341160
pii: 22/8/e531
doi: 10.1542/neo.22-8-e531
doi:
Substances chimiques
Antisickling Agents
0
Hydroxyurea
X6Q56QN5QC
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e531-e539Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL136904
Pays : United States
Informations de copyright
Copyright © 2021 by the American Academy of Pediatrics.